AngioDynamics (ANGO) investor relations material

Company transformation and strategic focus

• Shifted from serving interventional radiologists to targeting larger, high-growth cardiovascular and oncology markets.

• Divested non-core assets, increased R&D, and leveraged strategic M&A to support growth in expanding total addressable markets.

• Now operates in two segments: Med Tech (nearly 50% of revenue, high growth and margins) and Med Device (stable cash flow, funds Med Tech investments).

• Building a stronger commercial engine in Cardiovascular and Prostate markets to capture growth.

• Fiscal year starts June 1; FY 2027 has just begun, with results reported by segment.

Product innovation and market position

• Auryon laser system for peripheral arterial disease achieved #3 market share, surpassed $200M in cumulative sales, and was used in nearly 150,000 procedures since 2020.

• AlphaVac and AngioVac products address a $3B U.S. venous thromboembolism market, with AlphaVac receiving FDA clearance for pulmonary embolism after the APEX-AV study.

• NanoKnife, the only FDA-cleared IRE device for prostate tissue, targets solid tumor cancers and intermediate-risk prostate cancer, offering focal therapy with reduced side effects.

• NanoKnife received FDA indication and CPT 1 code, enabling broader reimbursement and accelerating adoption.

• Product pipeline targets $10.9B US TAM by FY31, expanding indications in cardiovascular and oncology markets.

Clinical and commercial momentum

• PRESERVE study and two-year follow-up show strong, durable outcomes for NanoKnife in prostate cancer, with no loss of continence or potency.

• NanoKnife recognized as a top invention by TIME and featured in AARP campaigns, boosting national visibility and expected to continue high double-digit growth.

• Recent favorable Medicare coverage decision expected to expand access and reimbursement for NanoKnife.

• Med Tech segment achieved a 25% CAGR, growing from $41M in FY20 to $127M in FY25, and is currently growing nearly 20%.

• Overall company growth at 9%, outpacing market and gaining share in all target categories.